W. Fitzsimmons

发表

Pharmacokinetic evaluation of the terfenadine-theophylline interaction.

S. Luskin, W. Fitzsimmons, C. MacLeod, 1989, The Journal of allergy and clinical immunology.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

J. Fay, R. Storb, S. Davies, 2000, Blood.

Impact of tacrolimus versus cyclosporine in hepatitis C virus‐infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial

G. Klintmalm, R. Busuttil, W. Fitzsimmons, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates1

I. Bekersky, M. Vu, Wenlei Jiang, 2003, Transplantation.

Lung Transplant Outcomes in Adults in the United States: Retrospective Cohort Study Using Real-world Evidence from the SRTR

D. Schladt, W. Fitzsimmons, T. Weaver, 2021, Transplantation.

Consensus Document: Therapeutic Monitoring of Tacrolimus (FK‐506)

U. Christians, W. Jusko, J. Fung, 1995 .

Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.

J. Melancon, S. Busque, J. Lake, 2007, Transplantation.

Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1‐Year Report

G. Ewald, S. Russell, L. Miller, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients.

R. Starling, C. Sigouin, G. Bhat, 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.

A. Matas, J. Pirsch, Joshua Miller, 2007, Transplantation.

The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity

R. Ghalie, W. Fitzsimmons, H. Kaizer, 2004, Cancer Chemotherapy and Pharmacology.

FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors.

J. Fay, H. Deeg, K. Sullivan, 1996, Blood.

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis.

I. Bekersky, W. Fitzsimmons, I. Lawrence, 2001, Journal of the American Academy of Dermatology.

Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation.

J. Fay, J. Wingard, R. Nash, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Assessment of Efficacy and Safety of FK778 in Comparison With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy

E. Woodle, M. First, W. Fitzsimmons, 2010, Transplantation.

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.

A. Deisseroth, K. Cleary, H. Fritsche, 1996, Blood.

Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey.

Junzheng Peng, I. Bekersky, M. Vu, 1998, Transplantation.

Tacrolimus and Minidose Methotrexate for Prevention of Acute Graft- Versus-Host Disease After Matched Unrelated Donor Marrow Transplantation

A. Deisseroth, K. Cleary, B. Andersson, 1996 .

Pentamidine Therapy in Renal Failure: Case Report and Literature Review

S. Luskin, W. Fitzsimmons, 1988, Drug intelligence & clinical pharmacy.

Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat.

S. Busque, M. Vu, L. Dumont, 1997, Transplantation.

PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1

M. Stegall, A. Henning, A. Gaber, 2004, Transplantation.

Prospective, Randomized, Multi‐Center Trial of Antibody Induction Therapy in Simultaneous Pancreas‐Kidney Transplantation

M. Stegall, A. Henning, S. Gruber, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.

R. Collins, J. Fay, J. Wingard, 1996, Blood.

Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat1

I. Bekersky, Wenlei Jiang, M. Hébert, 2003, Transplantation.

FK 506 ( Tacrolimus ) Monotherapy for Prevention of Graft-Versus-Host Disease After Histocompatible Sibling Allogeneic Bone Marrow Transplantation

R. Collins, J. Fay, J. Wingard, 2002 .

Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients

L. Shaw, L. Sarkozi, A. Shaked, 2001, Journal of clinical pharmacology.

Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients

J. Pirsch, S. McDiarmid, R. Venkataramanan, 2001, Pediatric transplantation.

RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION: RESULTS AT 2 YEARS1

M. Stegall, G. Danovitch, P. Halloran, 2001, Transplantation.

Cyclosporine Monitoring Improves Graft-Versus-Host Disease Prophylaxis after Bone Marrow Transplantation

R. Ghalie, W. Fitzsimmons, S. Manson, 1994, The Annals of pharmacotherapy.

Survey of Vancomycin Monitoring Guidelines in Illinois Hospitals

M. Postelnick, W. Fitzsimmons, P. V. Tortorice, 1988, Drug Intelligence & Clinical Pharmacy.

One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients

P. Kuo, M. Abouljoud, W. Fitzsimmons, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.

M. Stegall, G. Danovitch, P. Halloran, 2000, Transplantation.

Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation.

R A Nash, J. Fay, J. Wingard, 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.

R. Kershner, W. Fitzsimmons, 1996, Transplantation.

Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine.

M. Horowitz, J. Wingard, W. Fitzsimmons, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Pharmacologic Treatment of Human Polyomavirus Infection

W. Fitzsimmons, N. Ahsan, D. Laskow, 2002 .

Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients

H. Meier‐Kriesche, M. First, W. Fitzsimmons, 2014, Transplantation.

Meeting report: FDA public meeting on patient‐focused drug development and medication adherence in solid organ transplant patients

M. Dew, P. Nickerson, M. Chisholm-Burns, 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

A. Nademanee, J. Fay, R. Storb, 1998, Blood.

Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD

R. Nash, J. Denney, W. Fitzsimmons, 2001, Bone Marrow Transplantation.

Tacrolimus pharmacokinetics in BMT patients

J. Fay, J. Wingard, R. Nash, 1998, Bone Marrow Transplantation.

Phase III Study Comparing Methotrexate and Tacrolimus ( Prograf , FK 506 ) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

A. Nademanee, J. Fay, R. Storb, 1998 .

FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.

B. Blazar, P. Taylor, D. Vallera, 1994, Journal of immunology.

Effect of Two Administration Schedules of an Enteral Nutrient Formula on Phenytoin Bioavailability

W. Fitzsimmons, John M. Pellock, William E. Fitzsimmons, 1987, Epilepsia.

New‐Onset Diabetes After Transplantation: Results From a Double‐Blind Early Corticosteroid Withdrawal Trial

A. Henning, A. Gaber, J. Pirsch, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

New-Onset Diabetes After Transplantation (NODAT): An Evaluation of Definitions in Clinical Trials

M. First, W. Fitzsimmons, S. Dhadda, 2013, Transplantation.

Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.

H. Deeg, C. Yu, R. Huss, 1996, Bone marrow transplantation.

FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS

H. Deeg, M. Pepe, R. Storb, 1993, Transplantation.

Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients

J. Fay, J. Wingard, S. Devine, 1997, Bone Marrow Transplantation.

The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.

J. Wingard, S. Dix, H. Holland, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Demographic considerations in tacrolimus pharmacokinetics.

I. Bekersky, D. Dressler, Q. Mekki, 1998, Transplantation proceedings.

Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation

R. Ghalie, W. Fitzsimmons, C. Richman, 1993, American journal of hematology.

Once‐Daily Tacrolimus Extended‐Release Formulation: 1‐Year Post‐Conversion in Stable Pediatric Liver Transplant Recipients

M. Pescovitz, J. Keirns, M. First, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus.

Leslie M Shaw, L. Shaw, M. Korecka, 2002, Clinical chemistry.

Pharmacokinetics of prolonged‐release tacrolimus and implications for use in solid organ transplant recipients

N. Undre, J. Keirns, M. First, 2016, Clinical transplantation.

Modified release tacrolimus.

M. First, W. Fitzsimmons, 2004, Yonsei medical journal.

Effect of Corticosteroid Withdrawal on Tacrolimus and Mycophenolate Mofetil Exposure in a Randomized Multicenter Study

A. Henning, E. Woodle, A. Gaber, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years

M. Stegall, G. Danovitch, P. Halloran, 2003, Transplantation.

THE ROLE OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS KIDNEY (SPK) TRANSPLANT PATIENTS RECEIVING TACROLIMUS + MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESSION.: Abstract# 357

M. Stegall, R. Merion, G. Danovitch, 2000 .

In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non‐human primates

R. Morris, M. Stalder, W. Fitzsimmons, 2003 .

In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates

R. Morris, M. Stalder, W. Fitzsimmons, 2003, Transplant international : official journal of the European Society for Organ Transplantation.

NEW DRUGS TO IMPROVE TRANSPLANT OUTCOMES

M. First, W. Fitzsimmons, 2004, Transplantation.

Acute Rejection Characteristics From a Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Early Corticosteroid Withdrawal

A. Henning, A. Gaber, E. Woodle, 2013, Transplantation.